4.044

2.05% -0.096

Galectin Therapeutics Inc (GALT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.14

Offen:

$4.14

24-Stunden-Volumen:

189.72K

Relative Volume:

0.30

Marktkapitalisierung:

$408.44M

Einnahmen:

Nettoeinkommen (Verlust:

$-26.25M

KGV:

-9.8658

EPS:

-0.4099

Netto-Cashflow:

$-20.05M

1W Leistung:

+10.19%

1M Leistung:

+19.62%

6M Leistung:

+36.07%

1J Leistung:

-4.59%

1-Tages-Spanne:

$3.98

$4.20

1-Wochen-Bereich:

$3.58

$4.45

52-Wochen-Spanne:

$2.025

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Firmenname

Galectin Therapeutics Inc

Sektor

Healthcare (1088)

Branche

Biotechnology (605)

Telefon

678-620-3186

Adresse

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Mitarbeiter

Twitter

@galectingalt

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

GALT's Discussions on Twitter

Compare GALT vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GALT Galectin Therapeutics Inc	4.05	360.03M	0	-26.25M	-20.05M	-0.4099
VRTX Vertex Pharmaceuticals Inc	541.17	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	791.10	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,026.77	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.06	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.34	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-17	Fortgesetzt	H.C. Wainwright	Buy
2020-08-13	Bestätigt	H.C. Wainwright	Buy
2019-02-13	Eingeleitet	B. Riley FBR	Buy
2017-12-07	Bestätigt	H.C. Wainwright	Buy
2017-11-28	Bestätigt	H.C. Wainwright	Buy
2017-10-19	Eingeleitet	ROTH Capital	Buy
2017-03-30	Hochstufung	H.C. Wainwright	Neutral → Buy
2016-10-03	Herabstufung	FBR & Co.	Outperform → Mkt Perform
2016-09-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2016-09-28	Herabstufung	ROTH Capital	Buy → Sell
2016-03-28	Fortgesetzt	H.C. Wainwright	Buy
2015-09-21	Eingeleitet	H.C. Wainwright	Buy
2014-08-01	Herabstufung	Aegis Capital	Buy → Hold
2014-07-30	Bestätigt	MLV & Co	Buy
2014-07-29	Bestätigt	MLV & Co	Buy
2014-04-02	Bestätigt	MLV & Co	Buy
2014-02-10	Bestätigt	Aegis Capital	Buy
2014-01-09	Bestätigt	Aegis Capital	Buy
2013-12-03	Eingeleitet	MLV & Co	Buy
2013-08-19	Bestätigt	Aegis Capital	Buy

Alle ansehen

Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten

Aug 20, 2026

Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn

Aug 20, 2026

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn

Aug 20, 2026

Aug 18, 2026

HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat

Aug 18, 2026

Aug 17, 2026

Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn

Aug 17, 2026

Aug 15, 2026

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Aug 15, 2026

Aug 14, 2026

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat

Aug 14, 2026

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart

Aug 14, 2026

Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView

Aug 14, 2026

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView

Aug 14, 2026

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com

Aug 14, 2026

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative

Aug 14, 2026

Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo

Aug 14, 2026

GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView

Aug 14, 2026

Aug 13, 2026

Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat

Aug 13, 2026

Aug 10, 2026

Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 08, 2026